Skip to main content

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA

Director, Pharmacy Cancer Care
Assistant Professor of Pharmacy Mayo Clinic
Rochester, MN

Authored Items

505(b)(2) Drugs: New Chaos for Infusion Centers
By Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
September 2025, Vol 15, No 9
Reimbursement
Originally intended to foster innovation, such as extended-release formulations or novel delivery systems, recent years have seen a surge in 505(b)(2) applications for minor changes, such as vial size. Read More ›
Biosimilars—Are We There Yet?
By Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
March 2025, Vol 15, No 3
Biosimilars
The question remains: after 10 years of biosimilar availability in the United States and 20 years in Europe, are we there yet? Read More ›